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Introduction: High-risk neuroblastoma (HR-NB) presenting with hematogenous metastasis is one of the most
difficult cancers to cure. Patient survival is poor. Aggressive tumors contain populations of rapidly proliferating
clonogens that exhibit stem cell properties, cancer stem cells (CSCs). Conceptually, CSCs that evade intensive
multimodal therapy dictate tumor progression, relapse/recurrence, and poor clinical outcomes. Herein, we
investigated the plasticity and stem-cell related molecular response of aggressive metastatic neuroblastoma cells
that fit the CSC model.
Methods: Well-characterized clones of metastatic site-derived aggressive cells (MSDACs) from a manifold of metastatic
tumors of clinically translatable HR-NB were characterized for their CSC fit by examining epithelial-to-mesenchymal
transition (EMT) (E-cadherin, N-Cadherin), survival (NFκB P65, p50, IκB and pIκB) and drug resistance (ABCG2) by
immunoblotting; pluripotency maintenance (Nanog, SOX2) by immunofluorescence; and EMT and stemness related
transcription of 93 genes by QPCR profiling. Plasticity of MSDACs under sequential alternation of culture conditions
with serum and serum-free stem-cell conditions was assessed by clonal expansion (BrdU incorporation), tumorosphere
formation (anchorage independent growth), EMT and stemness related transcriptome (QPCR profiling) and validated
with MYC, SOX2, EGFR, NOTCH1 and CXCL2 immunoblotting.
Results: HR-NB MSDACs maintained in alternated culture conditions, serum-free stem cell medium to growth medium
with serum and vice versa identified its flexible revocable plasticity characteristics. We observed signatures of stem
cell-related molecular responses consistent with phenotypic conversions. Successive reintroduction to the favorable
niche not only regained identical EMT, self-renewal capacity, pluripotency maintenance, and other stem cell-related
signaling events, but also instigated additional events depicting aggressive adaptive plasticity.
Conclusions: Together, these results demonstrated the flexible plasticity of HR-NB MSDACs that typically fit the
CSC model, and further identified the intrinsic adaptiveness of the successive phenotype switching that clarifies
the heterogeneity of HR-NB. Moreover, the continuous ongoing acquisition of stem cell-related molecular
rearrangements may hold the key to the switch from favorable disease to HR-NB.Introduction
Neuroblastoma (NB), an extracranial solid tumor that
arises from neural crest components of the sympathetic
nervous system, is the most common cancer of infancy
[1,2]. Although neural crest cells undergo progressive
differentiation, there are subsets without differentiation
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when necessary, underscoring the developmental plasti-
city of this population [3,4]. The prognostic significance
of the cellular heterogeneity of neural crest lineage cells
in NB has begun to be described [5,6]. Clinical evidence
has recognized cell morphology diversity with the pres-
ence of a variety of neural crest cell types in neuroblast-
oma including neuroblasts, melanocytes, glial cells and
chondrocytes [7,8]. Clonal sublines from such neural
crest cells identified three distinct types including: (1)
small, rounded, loosely adherent cells with neurite-likel. This is an Open Access article distributed under the terms of the Creative
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fibroblast-like and highly substrate adherent cells, ‘S’
type; and (3) cells with intermediate morphology between
‘N’ and ‘S’ type cells, moderately substrate adherent and
having small numbers of neurite-like processes, ‘I’ type.
Further, studies have defined that both N and S type cells
descended from a common precursor cell, and are capable
of spontaneous bidirectional inter-conversion, ‘trans-dif-
ferentiation,’ which is a prevalent phenomenon among hu-
man neuroblastoma cell lines. More importantly, studies
have suggested I-type cells could represent a cellular inter-
mediate in the trans-differentiation process, and the
phenotypic conversion could be regulated by extrinsic
and/or intrinsic factors.
Clinically, a higher percentage of I-type cells associated
with augmented tumorigenicity as well as increased rates
of tumor relapse [9]. Interestingly, these cells expressed
CD133 and showed asymmetric cell division [9,10].
Other studies revealed that NB cells express neural pre-
cursor markers, including CD34, ABCG2 and nestin
[11-13]. Sixty-five percent of primary NB samples have
side populations, providing further evidence that NB is a
stem cell tumor [11]. Clinical and laboratory evidence
suggests that several common human cancers contain
populations of rapidly proliferating clonogens that can
have a substantial impact on tumor control following
therapy [14]. For many cancers, including NB, it has
been hypothesized that the tumor cells responsible for
failures in long-term remission exhibit stem cell proper-
ties [15-21]. Since more than half of the patients with
high-risk NB will relapse with hematogenous metastasis
[22] despite intensive multimodal therapy [23-32], we in-
vestigated the plasticity of stem-like aggressive NB cells.
Plasticity is the capability of a tumor cell to adapt to its
microenvironment and alter its phenotype.
Adult neural crest-derived cells have been shown to
retain stem cell properties [33]. Studies have consistently
demonstrated that such neural crest stem cell (NCSC)
populations often mimic transcription expression pro-
files of both embryonic stem cells and early neural crest
cells [34-36]. Recent breakthrough investigations recog-
nized the generation of induced pluripotent stem cells
(iPSCs) [34,36] and showed that iPSCs can be derived by
the manipulation of selective transcription factors. Given
high-risk NB’s heterogeneity, vigorous progression, and
therapy resistance, we hypothesize that selective ‘to-and-
from’ acquisition of genetic/molecular rearrangements
pertaining to the epithelial-to-mesenchymal transition
(EMT), pluripotency maintenance, self-renewal capacity,
and drug resistance may facilitate the better survival of
such aggressive clones. Studies have shown the progres-
sion of solid tumors from a minor population of cancer
stem cells (CSCs) with altered expression of selective
molecules, self-renewal capacity, and differentiation [37].These types of tumor cell subpopulations with altered
stem-like phenotypes have been identified in several
tumor systems, including leukemia, breast, brain and
colon cancers [38-41]. Neuroblastoma CSCs that ex-
hibit self-renewal and dynamic proliferation were also
capable of generating non-adherent tumorospheres
with enriched stemness [42]. Accordingly, we investigated
the ongoing continuous modifications in the stem cell-
related transcriptional machinery of aggressive metastatic
NB cells.
This study employed the derived clones of CSCs from
a manifold of metastatic tumors of a unique, validated,
and clinically translatable mouse model of high-risk ag-
gressive NB. Distinctively, the current study demonstrated
the potential plasticity of derived aggressive clones in se-
quentially alternated microenvironments ex vivo. Further,
a comprehensive, quantitative examination of stemness-
associated transcriptional machinery showed heightened
transcription of EMT-, pluripotency maintenance-, self-
renewal capacity-, and drug resistance-related molecules,
and identified plasticity-associated subsets of regained,
lost, or activated stem cell-related molecules, signifying
the plasticity and corresponding functional stem cell-




The parental human NB (SH-SY5Y) cell line obtained
from ATCC (Manassas, VA, USA) was cultured and main-
tained as described earlier [43]. We maintained metastatic
site-derived aggressive cell (MSDACs, Figure 1A) clones
that were established from the manifold of metastatic tu-
mors of a clinically mimicking animal model of human
high-risk metastatic disease ex vivo in serum-free stem
cell medium DMEM:F12 with 1% N2 supplement, 2%
B27 supplement, 20 ng/ml platelet-derived growth fac-
tor (hPDGF), 100 ng/ml epidermal growth factor (EGF),
and 1% antibiotic-antimycotic). High-risk aggressive
neuroblastoma animal model development and the der-
ivation of the MSDAC clones from multiple metastatic
tumors were reported elsewhere. MSDACs were se-
quentially characterized with karyotyping, whole gen-
ome array-Comparative Genome Hybridization (CGH)
analysis, whole genome gene expression, translational
expression of tumor progression-related proteins, miRNA
profiling, tumorosphere-forming capacity, and stemness
(unpublished data). In this study, early passages of derived
MSDACs were examined for their plasticity and associated
stemness-related transcriptional/translational alterations.
Cellular plasticity experiments
To determine the potential of aggressive MSDACs in
best-fit-survival in altered growing conditions and to
Figure 1 Morphometrics of the parental SH-SY5Y and metastatic site derived aggressive cells and the schematic representation of the
experimental workflow. (A) Representative light microscope photographs of parental SH-SY5Y cells and metastatic site-derived aggressive cells
(MSDACs) maintained in serum-free stem cell medium. Parental cells exhibited monolayer spreading with organized neurites (100 ×). MSDACs are
more spherical, smaller in size (100 ×), and formed organized tumorospheres (10 ×). (B) Schematic representation of experimental workflow: Three
well characterized individual clones of MSDACs were alternated between stabilized (three generations) microenvironment simulations with serum-free
stem cell medium to growth medium with serum and reintroduced back to serum-free stem cell medium. Parental cells grown in routine medium
and serum-free stem cell medium were included as controls. Cancer stem cell physiognomy, tumorosphere formation capacity, and transcriptional and
translational rearrangements associated with phenotype conversions were assessed at the end of each phase and in controls.
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examined their growth patterns and tumorosphere-
forming capacity ex vivo. A schematic representation of
the experimental workflow is presented in Figure 1B.
Briefly, isolated and characterized clones of MSDACs
from multiple metastatic tumors were maintained in
serum-free stem cell medium (SF-SCM-1) for three gen-
erations. At the end of the third generation, the cells
were transferred to the parental cell-culture conditions,
that comprises serum supplemented DMEM:F12
medium (growth medium with fetal bovine serum (GM-FBS)) without growth factors. Cells maintained in GM-
FBS for three generations were then re-introduced to
serum-free stem cell medium (SF-SCM-2). Parallel pri-
mary SF-SCM-1 and GM-FBS controls and phase-fixed
SF-SCM-1→GM-FBS controls were also included. Par-
ental SH-SY5Y cells grown in serum-free stem cell
medium served as a baseline control. All experiments
were repeated in triplicate utilizing alternate clones of
MSDACs. Cell loss and spreading, and formation of
well-organized tumorospheres, was assessed with phase
contrast light microscopy. In parallel, 1,000 cells plated
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tent real-time fluorescent imaging. Cells were stained
with DiI (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocar-
bocyanine perchlorate (‘DiI’; DiIC18(3)), Life Technolo-
gies, Grand Island, NY, USA), an orange-red-fluorescent
dye that is a long-term tracer for neuronal cells. Cells
were imaged in real-time once every 20 minutes for an
extended period of 18 hours using Operetta (Perkin
Elmer, Inc., Waltham, MA, USA). Sequential images
were reconstructed in Harmony (Perkin Elmer) to obtain
a time-lapse video. Cells were also harvested under each
experimental condition for subsequent endpoint analysis,
including transcriptional QPCR profiling, immunoblot-
ting, and high content quantitative immunofluorescence.
Quantitative EMT and stemness-related transcriptome
profiling
Total RNA extraction and real-time QPCR profiling
were performed as described earlier [44,45]. We used
custom-made transcriptome profilers (Realtimeprimers.
com) pertaining to stemness and EMT signaling. We ar-
chived a unique stem cell-related gene profile (Table S1
in Additional file 1) and constructed the QPCR profiler
in collaboration with realtimeprimers.com. We used this
highly selected QPCR profiler instead of an all-
encompassing gene array because the selected genes
provide a well-characterized profile governing EMT,
pluripotency maintenance, self-renewal capacity, and
drug resistance that direct the plasticity of these ag-
gressive cells. The ΔΔct values calculated by normaliz-
ing the gene expression levels to that of housekeeping
genes were then compared between groups. The rela-
tive expression level of each gene was expressed as fold
change. Group-wise comparisons were made using t-test
(for comparing SH-SY5Y versus MSDACs) and two-way
analysis of variance (ANOVA) with Tukey’s post-hoc
correction for comparing the gene loss, gain or regain in
MSDACs utilizing GraphPad PRISM.
Immunoblotting
Total protein extraction and immunoblotting were per-
formed as described in our earlier studies [43,46]. In this
study, the protein-transferred membranes were incubated
with rabbit polyclonal anti-MYC, anti-Sox-2(Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), anti-ABGC2,
and anti-nCadherin (Aviva Systems Biology Corp., San
Diego, CA, USA) antibodies, and mouse monoclonal anti-
NFκB-p65, anti-NFκB-p50, anti-eCadherin (Santa Cruz),
anti-NOTCH-1 (Pierce Biotechnology, Rockford, IL,
USA), and mouse polyclonal CXCL12 (eBioscience Inc.,
San Diego, CA, USA). Membranes were developed with
the appropriate anti-mouse/anti-rabbit (BioRad Labora-
tories, Hercules, CA, USA) secondary antibody. Blots were
stripped and reblotted with rabbit polyclonal anti-β-actinantibody (Gentex Inc., Irvine, CA, USA) or anti-α-tubulin
to determine equal loading of the samples. Densitometry
analysis was performed using Quantity One gel analysis
software (BioRad). α-tubulin or β-actin normalized values
are compared between groups using t-test or two way
ANOVA with Bonferoni’s post hoc correction (GraphPad
Prism) and a P value of less than one is considered statisti-
cally significant.
Bromodeoxyuridine-incorporation assay
SH-SY5Y cells and the MSDACs grown in SF-SCM-1
(3G), SF-SCM-1(3G)→GM-FBS(3G), or SF-SCM-1
(3G)→GM-FBS(3G)→ SCM-2(3G) were treated with
bromodeoxyuridine (BrdU) (1 μM) for 2 hours, washed
and fixed in sucrose supplemented 3% paraformalde-
hyde in PBS. Fixed cells were serially treated with 0.1%
triton buffer and 2 M HCl with excessive intermittent
PBS washing. The cells were then blocked (0.1% BSA
in PBS), tagged with anti-BrdU mouse antibody (for
1 hour at 37°C), washed and second labelled with goat-
anti mouse Alexa Fluor-488. Unlabeled nuclei were then
stained with 4',6-diamidino-2-phenylindole (DAPI) and
analyzed in Operetta high content confocal imaging.
Experiments are repeated three times and for each well
25 different fields in 14 different Z planes were cap-
tured. Quantification of the BrdU incorporated nuclei
are counted using Operetta integrated Columbus
software.
Anchorage-independent soft agar assay
MSDACs grown in SF-SCM-1(3G), SF-SCM-1(3G)→
GM-FBS(3G), or SF-SCM-1(3G)→GM-FBS(3G)→ SCM-
2(3G) were suspended in defined medium containing 0.3%
agar and seeded into 24-well culture plates. To avoid cell
attachment, culture plates were pre-coated with 0.5% agar
before cell seeding. Cultures were fed with fresh medium
every three to five days and cultured for fourteen days. Col-
onies developed were fixed with 3.7% paraformaldehyde
and stained with 0.1% crystal violet and imaged with the
Vista-Vision Inverted trinocular microscope equipped with
Moticam 5MP CMOS camera.
High content confocal immunocytofluorescence
We examined the cellular localization and expression
levels of SOX2 and Nanog in parental SH-SY5Y and in
multiple clones of MSDACs using Operetta (Perkin
Elmer) high content and quantitative confocal imaging.
Paraformaldehyde-fixed SH-SY5Y cells and MSDACs
were permeabilized (0.25% Triton X-100), blocked (1%
BSA in PBS), and labelled with rabbit polyclonal anti-
SOX2 and anti-nanog antibody (1: 200, Santa Cruz).
Then, they were tagged with Alexa Fluor 488 fluoro-
chrome conjugated anti-mouse secondary antibodies
(Abcam). The nucleus was counter-labeled with DAPI.
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least eight fields/well and three wells/clone, with a mini-
mum of 21 Z planes. Unstained controls were included
for both cell lines. Columbus software (Perkin Elmer)
was used for quantitative image analysis.
Results
MSDACs from high-risk metastatic disease exhibited
heightened stemness and fit the neuroblastoma cancer
stem cell profile
All MSDACs clones exhibited consistent uncontrolled
growth in SF-SCM. Compared with the parental SH-SY5Y
cells that have structured neurites, MSDACs are smaller in
size and readily form organized tumorospheres (Figure 1A).
Immunoblot analysis and high content confocal immuno-
fluorescence (IF) revealed activated stem cell characteristics
and cell survival signaling in MSDACs (Figure 2). We ob-
served a robust activation of the EMT marker N-cadherin
in MSDACs compared with parental SH-SY5Y cells.
E-Cadherin was significantly (P <0.001) reduced in MSDACs,
demonstrating an active EMT (Figure 1A). Likewise, we
observed a significant (P <0.001) increase in the expres-
sion of the drug-resistance molecule AGBCG2 in
MSDACs. Immunoblotting revealed a profound increase
in the expression of the transcriptional switch NFκB that
promotes cell survival. We observed a significant increase
in the expression of NFκB-p65 and p50 in MSDACs, the
heterodimeric formation of which functions as a transcrip-
tional regulator (Figure 2A). Consistently, we observed a
definite increase in IκB phosphorylation, indicating the re-
lease of NFκB from the cytoplasm. We found no alterations
in the constitutive levels of IκB (Figure 2a). Moreover, the
results of the high content IF analysis showed a strong plur-
ipotency maintenance activity in MSDACs. We observed a
significant increase in the expression levels of pluripotency-
maintaining SOX2 and NANOG in various clones of
MSDACs (Figure 2B), compared with the parental SH-
SY5Y cells. Further, comprehensive EMT and stem cell-
related quantitative transcriptional profiling revealed
significant increases in the transcription of 29 stem cell-
related molecules in MSDACs: BMP2, BMP3, BMP4,
BTRC, CD4, CD8A, CDX2, COL1A1, CTNNA1, CXCL12,
DHH, DLL1, DVL1, EGF2, EGF4, EGFR1, FRAT, GJB2,
HDAC2, IGF1, KRT15, LIN28, MSX1, NOTCH2, OCLN,
SIGMAR1, SNAI2, SOX2, and TWIST1 (Figure 2C). Par-
ental SH-SY5y cells did not display increased transcription
of these molecules. Together, these results suggest that the
derived clones of MSDACs possess activated machinery
that drives cell survival, EMT, drug resistance, and pluri-
potency maintenance.
MSDACs exerted high levels of cellular plasticity
To underscore the plasticity of the MSDACs, we
adopted sequential alternations of the culture conditions.A schematic representation of the experimental work
flow is provided in Figure 1B. Parallel populations from
three different MSDAC clones were examined for cell
growth physiognomies, including proliferation, spreading
or aggregation, and tumorosphere formation under dif-
ferent culture conditions. To further highlight cellular
plasticity and avoid the possibility of delayed cell re-
sponse inference, we maintained the populations for at
least three generations under each culture condition.
BrdU incorporation assay revealed a baseline prolifera-
tion in parental SH-SY5Y cells (Figure 3A lower panel).
MSDACs (SF-SCM-1) on the other hand, showed an in-
creased proliferation rate. Conversely, the proliferation
rate was much slower in SF-SCM-1(3G)→GM-FBS(3G)
MSDACs (Figure 3A). Notably, MSDACs reintroduced
into the stem cell medium (SF-SCM-1(3G)→GM-FBS
(3G)→ SCM-2(3G)) demonstrated not only the regain-
ing of cell proliferation, but also exhibited a heightened
cell proliferation level (Figure 3A). Quantification of the
BrdU incorporated nuclei recognized: significant (P <0.001)
decrease in cell proliferation when MSDACs are introduced
to GM-FBS; robust (P <0.001) increase when these
cells are reintroduced to SF-SCM; and relatively ampli-
fied (P <0.001) cell proliferation in SF-SCM-2 as that
of SF-SCM-1 (Figure 3B).
Parental SH-SY5Y cells grown in routine medium
showed uniform monolayer spreading with no cellular
aggregation or tumorosphere formation (Figure 4). Like-
wise, SH-SY5Y cells maintained in SF-SCM demonstrated
monolayer spreading without tumorosphere formation.
Cell spreading was relatively slower in such conditions. A
few populations showed initial cell aggregation, but did
not form any organized tumorospheres (Figure 4B). How-
ever, MSDACs grown in SF-SCM consistently formed
organized tumorospheres across generations. The cell pro-
liferation rate was evidenced by the increased size and
number of tumorospheres (Figure 4A). A known number
of cells from the third generation were stained with DiI
and observed in real-time for a period of 18 hours. Stain-
ing revealed tumorosphere formation without monolayer
cell spreading (Figure S1 in Additional file 2). Single cell
suspensions obtained from tumorospheres of SF-SCM-1
(3G) that were transferred to GM-FBS culture conditions
exhibited parental cell-like monolayer spreading without
tumorosphere formation. Consistent with the SH-SY5Y
cells, these populations showed an initial cell aggregation,
but formed no tumorospheres (Figure 4A). High content
sequential observations of these populations (SF-SCM-1
(3G)→GM-FBS(3G)) revealed no tumorosphere forma-
tion and further demonstrated a monolayer differentiation
(Figure S2 in Additional file 3). Interestingly, SF-SCM-1
(3G)→GM-FBS(3G) cells reintroduced to serum-free
stem cell medium (SF-SCM-2) showed robust and orga-
nized tumorosphere formation despite their demonstrated
Figure 2 Cancer stem cell characterization of MSDACs. (A) Immunoblotting analysis showing activated EMT (increased N-cadherin and decreased
E-cadherin), drug resistance (increased ABCG2), and survival response (increased p65/p50 and pIκBα) in MSDACs compared with parental SH-SY5Y cells.
(B) High content confocal immunofluorescence showing increased expression levels of pluripotency maintenance factors SOX2 and NANOG in three
different clones of MSDACs. (C) Results of QPCR profiling analysis showing transcriptional activation of 29 stem cell-related molecules in MSDACs
maintained in serum-free stem cell medium, compared with SH-SY5Y cells. EMT, epithelial-to-mesenchymal transition; MSDACs, metastatic site-derived
aggressive cells.
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(Figure 4A). Notably, these MSDACs (SF-SCM-1(3G)→
GM-FBS(3G)→ SCM-2(3G)) are more aggressive, as evi-
denced by the formation of more and larger tumoro-
spheres (Figure S3 in Additional file 4).
Further, anchorage-independent cell growth assay ex-
hibited marked numbers of defined colonies with SF-
SCM-1(3G) MSDACs (Figure 4C). Evidently, soft-agarcolony formation capability was completely reduced in
SF-SCM-1(3G)→GM-FBS(3G) MSDACs. Conversely,
MSDACSs reintroduced into the SF-SCM-2 (SF-SCM-1
(3G)→GM-FBS(3G)→ SCM-2(3G)) profoundly exhib-
ited colony formation in soft agar. Relatively, the colonies
formed by the cells from SF-SCM-2 were morphometric-
ally bigger in a given period of time (Figure 4C). These
phase specific anchorage-independent cell growth
Figure 3 Modulations in cell proliferation levels of MSDACs under alternated culture conditions. A) Representative microphotographs of
random fields obtained from Operetta high-content confocal imaging showing BrdU incorporation levels in three different clones of MSDACs
maintained in serum-free stem cell medium for three generations: SF-SCM-1(3G), SF-SCM-1(3G) cells transferred and maintained in growth
medium with FBS for three generations (SF-SCM-1(3G)→GM-FBS(3G), or the MSDACs reintroduced in SF-SCM for three generations (SF-SCM-1(3G)→
GM-FBS(3G)→ SF-SCM-2(3G). Parental SH-SY5Y cells maintained in growth medium are used as controls. B) Histograms obtained from Columbus
image analysis showing significant decline in BrdU positive cells in SF-SCM-1(3G)→GM-FBS(3G) MSDACs and regained and amplified cell proliferation
in MSDACs reintroduced in SF-SCM (SF-SCM-1(3G)→ GM-FBS(3G)→ SF-SCM-2(3G). Brd-U, bromodeoxyuridine; MSDACs, metastatic site-derived
aggressive cells.
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mation as well as cell proliferation data. Taken together,
these results demonstrate that the human neuroblastoma
MSDACs derived from a manifold of metastatic tumors
are extremely plastic, depending on the environmental influ-
ence, and further show that these MSDACs can aggressively
regain tumorigenic capacity given an appropriate niche .
Plasticity and aggression of human neuroblastoma
MSDACs substantiates altered stemness machinery
To further substantiate our findings and underscore the
associated alterations in stem cell-related signaling inthis setting, we first investigated the plasticity-associated
alterations in stem cell-related transcriptional machin-
ery. We used a custom–made quantitative QPCR profile
of stem cell-related molecules that govern EMT, self-
renewal capacity, pluripotency maintenance, and drug
resistance. Data mining of these altered transcriptional
responses between the SCM-1(3G); SCM-1(3G)→GM-
FBS(3G) and SCM-1(3G)→GM-FBS(3G)→ SCM-2(3G)
populations revealed three distinct clusters of genes in-
cluding: (1) activation regained; (2) activation lost; and;
(3) activation gained. Overall, the following 20 stem cell-
related genes that were significantly activated in SCM-1
Figure 4 Tumorosphere formation and anchorage independent growth capabilities of MSDACs in alternated culture conditions. (A)
Representative microphotographs showing growth trends, monolayer differentiation or cell aggregation, tumorosphere formation, and
phenotype conversions in three different clones of MSDACs maintained in serum-free stem cell medium for three generations: SF-SCM-1(3G),
SF-SCM-1(3G) cells transferred and maintained in growth medium with FBS for three generations (SF-SCM-1(3G)→ GM-FBS(3G), or the MSDACs
reintroduced in SF-SCM for three generations (SF-SCM-1(3G)→ GM-FBS(3G)→ SF-SCM-2(3G). (B) Parental SH-SY5Y cells maintained in growth
medium or SF-SCM are used as controls. (C) Representative microphotographs of soft agar colony forming assay showing anchorage-independent
growth signatures of MSDACs maintained in serum-free stem cell medium for three generations, transferred and maintained in growth medium with
FBS for three generations or reintroduced in SF-SCM for three generations. FBS, fetal bovine serum; MSDACs, metastatic site-derived aggressive cells;
SF-SCM, serum-free stem cell medium.
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regained in SCM-1(3G)→GM-FBS(3G)→ SCM-2(3G):
ASCL2, BGLAP, CDX2, COL1A1, COL2A1, CXCL12,
DVL1, EGF2, EGFR1, FRAT, GJB1, GJB2, IGF1, KRT15,
LIN28, PPARG, SIGMAR1, SNAI1, SNAI2, and SOX2
(Figure 5A). Reactivation of these molecules when the
cells are reintroduced into the SF-SCM demonstrates the
association of stem cell signaling with acquired plasticityin these MSDACs. However, the following 13 genes that
were activated in SCM-1(3G) were completely lost in
SCM-1(3G)→GM-FBS(3G)→ SCM-2(3G): BMP2, BMP4,
BTRC, CD4, CD44, CD8A, COL9A1, CTNNA1, DHH,
DLL1, EGF4, GDF3 and TWIST1 (Figure 5B). In contrast
with the other two conditions, 25 genes showed significant
activation in SCM-1(3G)→GM-FBS(3G)→ SCM-2(3G):
ADAR, ALDH1A1, AXIN1, CD9, CDH2, DLL3, DTX1,
Figure 5 QPCR profiling identifies regained and/or lost transcription of EMT and stem cell molecules in MSDACs cultured under
alternated growth conditions. (A) Histograms of QPCR profiling analysis showing stem cell-related transcriptional responses regained with the
reverted CSC phenotype when MSDACs are reintroduced into SF-SCM. Interestingly, the rescue of stem cell transcriptional responses is relatively
heightened when compared with the earlier CSC phenotype stage. (B) Histograms showing the panel of stem cell-related molecules that were
significantly lost in the second phase CSC phenotype. Almost all of these molecules showed decreased expression in the non-favorable niche
(GM-FBS) and never regained expression when returned to a favorable environment. CSC, cancer stem cell; EMT, epithelial-to-mesenchymal transition;
GM-FBS, growth medium with fetal bovine serum; MSDACs, metastatic site-derived aggressive cells; SF-SCM, serum-free stem cell medium.
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MYOD1, NOTCH2, MYST1, MYST2, NCAM1, PDX1,
PPARD, S100B, SHH, and TGFB1 (Figure 6A). Robust
activation of these molecules in the MSDACs that were
reintroduced to the SF-SCM demonstrates the ongoing
acquisition of molecular rearrangements in MSDACs,
and could drive the aggressive phenotype.
Immunoblotting analysis for selective proteins vali-
dated the observed transcriptional alterations and por-
trayed the translation of the response at the protein
level. Compared with the parental SH-SY5Y cells, we
observed a significant (P <0.001) activation of MYC,
SOX2, EGFR, and CXCL12 in MSDACs (Figure 6B).
This induced expression of MYC, SOX2, EGFR, and
CXCL12 was lost in SF-SCM-1(3G)→GM-FBS(3G)MSDACs. However, the lost expression was signifi-
cantly regained in SF-SCM-1(3G)→GM-FBS(3G)→
SF-SCM-2(3G) MSDACs (Figure 6B). Expression of
NOTCH1 was lost in the SF-SCM-1(3G)→GM-FBS
(3G)→ SF-SCM-2(3G) population. These results support
the transcriptional data. Taken together, the transcrip-
tional profiling and immunoblotting analysis demon-
strate a significant association between the alterations
of EMT, self-renewal capacity, pluripotency mainten-
ance, and other stem cell-related signaling responses
and the plasticity of the MSDACs. In addition, mole-
cules that were only activated in the third phase sug-
gested the continuous ongoing acquisition of stemness
and drug resistance, which could explain the additional
aggressiveness of this population.
Figure 6 Adaptive plasticity of stemness signaling in MSDACs cultured under alternated growth conditions. (A) Histograms of QPCR
profiling analysis showing stem cell-related transcriptional responses that were exceptionally activated with the regaining of the CSC phenotype
under favorable niche conditions. These molecules did not show either loss or gain under the early CSC stage or the unfavorable and differentiated
stage, but demonstrated a robust and significant activation when the MSDACs regained their CSC status, suggesting an intrinsic adaptive gain
in stemness. (B) Representative blots showing the phenotypic conversion associated translational modifications in MYC, SOX2, EGFR, NOTCH1,
and CXCL12. The phenotype-dependent modifications of these proteins corroborated well with their transcriptional expression data and validated the
regain of the CSC status. CSC, cancer stem cell; MSDACs, metastatic site-derived aggressive cells.
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Clinical outcomes for neuroblastoma vary greatly de-
pending on stage and risk status. Patients with stage 1
and 2 disease are more likely to survive, as the disease
will disappear with spontaneous maturation or regres-
sion, while patients with stage 4 and 4 s disease present
with hematogenous metastasis, relapse/recurrence after
therapy, and experience a dramatic decline in overall
survival [22,31,47]. Studies worldwide, including those
from our laboratory, focus on identifying the molecular
drivers that switch favorable neuroblastoma to high-risk
metastatic disease. Identifying these drivers could shift a
huge archetype in the current treatment practice and
benefit innumerable children with neuroblastoma.
Human cancers have been shown to contain popula-
tions of rapidly proliferating clonogens that can have a
substantial impact on tumor control [14]. These tumorcells are responsible for failures in long-term remission
and exhibit stem cell properties [15-21]. Conceptually,
CSCs, a small subset of cells, constitute a reservoir of
self-sustaining cells with the exclusive ability to self-renew
and to spawn the heterogeneous lineages of cancer
cells that comprise the tumor [48]. Emerging evidence
from multiple tumor systems, including neuroblast-
oma, recognizes the driving role of such CSCs in
tumor progression, relapse, recurrence, and poor clin-
ical outcomes [49-51]. Researchers have postulated the
unidirectional and bi-directional plasticity of these
CSCs and highlighted their significance in tumor pro-
gression events [52,53]. In the current study, we exam-
ined the reversible and intrinsic adaptive plasticity of
the human neuroblastoma MSDACs derived from clin-
ically mimicking and translatable spontaneous high-
risk metastatic tumors.
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onstrate the reversible adaptive plasticity in aggressive
neuroblastoma cells obtained from metastatic tumors.
The MSDACs utilized for this study are well character-
ized and their cytogenetic, genetic, and molecular physi-
ognomies are documented (data reported elsewhere).
The results of the present study define their heightened
survival characteristics, stem-like phenotype, and stem
cell-related molecular blueprint. This is evident with the
amplified expression of EMT, drug resistance, and pluri-
potency maintenance molecular response, as well as other
stem cell-related transcriptional machinery (see Figure 2).
These data validate the conceptual hypothesis that aggres-
sive metastatic cells exhibit stem cell properties [15-21].
Utilizing validated human MSDACs that characteristically
fit the CSC model to elucidate and typify plasticity allows
us to closely relate these outcomes to clinical settings.
Despite extensive neuroblastoma research recognizing the
influence of CSCs on prognosis and clinical practices
purging CSCs, our knowledge regarding CSC plasticity is
limited. Chakrabarti and colleagues demonstrated the re-
versible plasticity of neuroblastoma cells [54] and further
recognized the mechanism linking Id2 and TGFβ in drug-
associated adaptive plasticity [55]. Consistently, our results
demonstrated and validated the reversible plasticity in
neuroblastoma cells. For the first time, this study ex-
plained neuroblastoma cells’ phenotype switching in
MSDACs that typically fit the CSC model. Further, this
study identified the intrinsic adaptiveness of the successive
phenotype switching that clarifies the heterogeneity of ag-
gressive neuroblastoma. This continuous ongoing acquisi-
tion of molecular rearrangements pertaining to stem cell-
related signaling may drive the switch from favorable dis-
ease to aggressive neuroblastoma.
In addition to the reversible phenotypical changes ex-
hibited by metastatic CSC-like cells, we observed the
rescue of stem cell-related molecules. More importantly,
we identified a cluster of activated molecules in the third
phase (SF-SCM-1(3G)→GM-FBS(3G)→ SF-SCM-2(3G)),
consistent with adaptive plasticity. Identification of the stem
cell-related molecular markers of SF-SEM-1(3G) and
SF-SEM-2(3G) phenotypes allowed us to demonstrate
that reversible adaptation is a definite process during
tumor growth. The concept of CSC has gained support
due to the indefinite tumorigenic potential, pluripotency
maintenance, self-renewal capacity, and drug resistance
of the proposed cells.
Although our results are consistent with this notion,
showing a near-identical tumorosphere-forming capacity
and stem cell-related molecular expression profiling, we
also identified an added molecular response, demonstrat-
ing adaptive plasticity. As discussed above, this finding
supports the hypothesis of cancer cell plasticity-associated
tumor heterogeneity. Continuous ongoing acquisitions ofmolecular rearrangements in CSC seem to better enhance
the plasticity and tumorigenic capacity of these cells.
The authors acknowledge the limitations of this study,
including our analysis of pathway- focused stem cell-
related transcriptional machinery rather than a whole
genome approach, and that all experiments were con-
fined to an ex vivo approach. However, these aggressive
cells evade multimodal therapy and drive tumor progres-
sion in clinical settings while exhibiting CSC physiogno-
mies. Further, stem cell-related molecular machinery has
been shown to play a crucial role in phenotypic conver-
sions. Hence, it is appropriate to identify stem cell ma-
chinery in neuroblastoma cells’ reversible and adaptive
plasticity. The whole genome approach is beyond the
scope of this manuscript. Investigation of the tumori-
genic and metastatic potential of these cells under differ-
ent phenotypes and the functional mechanism that
instigates plasticity and high-risk aggressive disease are
warranted and are currently underway in our laboratory
with appropriate animal models.
Conclusions
In conclusion, the results presented here for the first time
show that aggressive MSDACs from high-risk metastatic
disease fitting the CSC model are dynamically plastic and
phenotypically respond to their microenvironment. These
cells possess stem-like characteristics and are continu-
ously acquiring molecular transitions that are needed
to optimize their capacity to survive in a changing en-
vironment. It is evident that these cells inherit adaptive
and additional molecular rearrangements that favor
phenotype conversions on an as and when needed
basis. Such a reversible and adaptive plasticity in highly
metastatic CSC-like neuroblastoma cells may, hence,
determine the clinical behavior and treatment response
of neuroblastoma.
Additional files
Additional file 1: Table S1. List of 93 stem-cell related genes, their
Entrez gene name, cellular location, functional type and their known
biomarker applications in the custom made Stemness/EMT transcriptome
QPCR profiler examined in the current study.
Additional file 2: Figure S1. Sequential images from a representative
field obtained from high-content, time-lapse fluorescent imaging of
DiI-stained MSDACs maintained in serum-free stem cell medium
(SF-SCM-1). Cells were imaged in real time once every 20 minutes for
an extended period of 18 hours using Operetta. MSDACs cultured in
SF-SCM-1 showed significant cell proliferation and organized
tumorosphere formation.
Additional file 3: Figure S2. Sequential images obtained from time-lapse
fluorescent imaging of MSDACs that were grown in SF-SCM-1 for three
generations and subsequently maintained in growth medium supplemented
with 10% FBS (GM-FBS) for an additional three generations. MSDACs cultured
in SF-SCM-1 (3G)→ GM-FBS(3G) showed consistent cell proliferation and
monolayer spreading without any cellular aggregation or tumorosphere
formation.
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time-lapse fluorescent imaging of MSDACs that were grown in SF-SCM-1
(3G)→ GM-FBS(3G) and subsequently reintroduced to the second phase
of SF-SCM (SF-SCM-2) for an additional three generations. MSDACs
cultured in SF-SCM-1 (3G)→ GM-FBS(3G)→ SF-SCM-2(3G) showed robust
cell proliferation and consistent tumorosphere formation.
Abbreviations
ANOVA: analysis of variance; Brd-U: bromodeoxyuridine; BSA: bovine serum
albumin; CSCs: cancer stem cells; DAPI: 4',6-diamidino-2-phenylindole;
DiI: 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate; (D)
MEM: (Dulbecco’s) modified Eagle’s medium; EGF: epidermal growth factor;
EMT: epithelial-to-mesenchymal transition; GM-FBS: growth medium with
fetal bovine serum; HR-NB: high-risk neuroblastoma; IF: immunofluorescence;
iPSCs: induced pluripotent stem cells; miRNA: microRNA; MSDACs: metastatic
site-derived aggressive cells; NB: neuroblastoma; NCSC: neural crest stem cell;
PBS: phosphate-buffered saline; SF-SCM-1: serum-free stem cell medium.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NA designed the experiments and drafted the manuscript. VP, SR, FHK and
TA performed the experiments. FHK and SR contributed to data analysis and
helped to draft the manuscript. NA and VP contributed to statistical tests. All
authors read and approved the final manuscript.
Acknowledgements
The authors are supported by the National Institutes of Health (NIH
1P20GM103639-01) from the COBRE Program of the National Institutes of
Health to N. Aravindan. The authors acknowledge the SCC Cancer functional
genomics core for high content confocal imaging, and the OUHSC flow
cytometry and imaging core for the cell sorting services. The authors also
acknowledge the OUHSC staff editor (Ms. Kathy Kyler) for help in critically
reviewing this manuscript.
Received: 24 October 2014 Revised: 3 February 2015
Accepted: 3 February 2015 Published: 20 February 2015
References
1. Marc TG, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system
tumors. In: Cancer incidence and survival among children and adolescents:
United States SEER Program 1975–1995. Bethesda, MD: National Cancer
Institute; 1999. p. 65–72. NIH Pub. No. 99-4649(ICCC IV).
2. Gurney JG, Smith MA, Ross JA. Cancer among infants. In: Cancer incidence
and survival among children and adolescents: United States SEER Program
1975–1995. Bethesda, MD: National Cancer Institute; 1999. p. 149–56. NIH
Pub. No. 99–4649 (XII).
3. Fernandes KJ, Miller FD. Isolation, expansion, and differentiation of mouse
skin-derived precursors. Methods Mol Biol. 2009;482:159–70.
4. Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and characterization of
multipotent skin-derived precursors from human skin. Stem Cells.
2005;23:727–37.
5. Shimada H, Chatten J, Newton Jr WA, Sachs N, Hamoudi AB, Chiba T, et al.
Histopathologic prognostic factors in neuroblastic tumors: definition of
subtypes of ganglioneuroblastoma and an age-linked classification of
neuroblastomas. J Natl Cancer Inst. 1984;73:405–16.
6. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, et al.
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are
susceptible to a targeted oncolytic virus. PLoS One. 2009;4:e4235.
7. DeClerck YA, Bomann ET, Spengler BA, Biedler JL. Differential collagen
biosynthesis by human neuroblastoma cell variants. Cancer Res.
1987;47:6505–10.
8. Tsokos M, Scarpa S, Ross RA, Triche TJ. Differentiation of human
neuroblastoma recapitulates neural crest development. Study of
morphology, neurotransmitter enzymes, and extracellular matrix proteins.
Am J Pathol. 1987;128:484–96.
9. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, et al.
Characteristics of stem cells from human neuroblastoma cell lines and in
tumors. Neoplasia. 2004;6:838–45.10. Ross RA, Spengler BA. Human neuroblastoma stem cells. Semin Cancer Biol.
2007;17:241–7.
11. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al.
A distinct “side population” of cells with high drug efflux capacity in human
tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228–33.
12. Islam MO, Kanemura Y, Tajria J, Mori H, Kobayashi S, Hara M, et al.
Functional expression of ABCG2 transporter in human neural stem/progenitor
cells. Neurosci Res. 2005;52:75–82.
13. Thomas SK, Messam CA, Spengler BA, Biedler JL, Ross RA. Nestin is a
potential mediator of malignancy in human neuroblastoma cells. J Biol
Chem. 2004;279:27994–9.
14. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of
S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Semin Oncol. 1992;19:21–8.
15. Yu F, Sim AC, Li C, Li Y, Zhao X, Wang DY, et al. Identification of a
subpopulation of nasopharyngeal carcinoma cells with cancer stem-like cell
properties by high aldehyde dehydrogenase activity. Laryngoscope.
2013;123:1903–11.
16. Vu NB, Nguyen TT, Tran LC, Do CD, Nguyen BH, Phan NK, et al. Doxorubicin
and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like
properties. Cytotechnology. 2013;65:491–503.
17. Torigoe T, Hirohashi Y, Yasuda K, Sato N. Constitutive expression and
activation of stress response genes in cancer stem-like cells/tumour
initiating cells: potent targets for cancer stem cell therapy. Int J Hyperthermia.
2013;29:436–41.
18. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. Cancer cells acquire a drug
resistant, highly tumorigenic, cancer stem-like phenotype through
modulation of the PI3K/Akt/beta-catenin/CBP pathway. Int J Cancer.
2014;134:43–54.
19. Hardin H, Montemayor-Garcia C, Lloyd RV. Thyroid cancer stem-like cells
and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol.
2013;44:1707–13.
20. Hu X, Ghisolfi L, Keates AC, Zhang J, Xiang S, Lee DK, et al. Induction of
cancer cell stemness by chemotherapy. Cell Cycle. 2012;11:2691–8.
21. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig
Z, Cecchini MG, et al. Stem-like cells with luminal progenitor
phenotype survive castration in human prostate cancer. Stem Cells.
2012;30:1076–86.
22. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet.
2007;369:2106–20.
23. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for
relapsed neuroblastoma: challenges on the road to precision therapy. J Ped
Hematol Oncol. 2013;35:337–47.
24. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D,
et al. Long-term results for children with high-risk neuroblastoma treated
on a randomized trial of myeloablative therapy followed by 13-cis-retinoic
acid: a children’s oncology group study. J Clin Oncol. 2009;27:1007–13.
25. Cole KA, Maris JM. New strategies in refractory and recurrent
neuroblastoma: translational opportunities to impact patient outcome. Clin
Cancer Res. 2012;18:2423–8.
26. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals
in high-risk neuroblastoma. Cancer. 2008;112:2796–801.
27. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B.
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma:
results of German trials. Pediatr Blood Cancer. 2011;56:578–83.
28. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing
survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol.
2004;26:227–32.
29. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al.
Outcomes for children and adolescents with cancer: challenges for the
twenty-first century. J Clin Oncol. 2010;28:2625–34.
30. Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, et al. The
recurrence patterns of stages I, II and III neuroblastoma: experience with 77
relapsing patients. Ann Oncol. 1996;7:183–7.
31. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, et al.
Outcome of children with neuroblastoma after progression or relapse. A
retrospective study of the Italian neuroblastoma registry. Eur J Cancer.
2009;45:2835–42.
32. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic
syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for
relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003;25:543–7.
Pandian et al. Stem Cell Research & Therapy 2015, 6:400 Page 13 of 13
http://stemcellres.com/content/6/1/40033. Sieber-Blum M, Hu Y. Mouse epidermal neural crest stem cell (EPI-NCSC)
cultures. J Vis Exp. 2008;15:772.
34. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming
of human somatic cells to pluripotency with defined factors. Nature.
2008;451:141–6.
35. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell.
2006;126:663–76.
36. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced
pluripotent stem cells free of vector and transgene sequences. Science.
2009;324:797–801.
37. Almanaa TN, Geusz ME, Jamasbi RJ. A new method for identifying stem-like
cells in esophageal cancer cell lines. J Cancer. 2013;4:536–48.
38. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med.
1997;3:730–7.
39. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A.
2003;100:3983–8.
40. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification
of human brain tumour initiating cells. Nature. 2004;432:396–401.
41. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell
capable of initiating tumour growth in immunodeficient mice. Nature.
2007;445:106–10.
42. Liu QX, Tang JY, Cai JY, Yin MZ, Li BS. The cultivation and identification of
tumor stem cells from neuroblastoma derived tumor spheres. Chin J
Cancer. 2010;29:1012–7.
43. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N.
Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB
cross-signaling favors survival advantage in human neuroblastoma
cells. J Biol Chem. 2011;286:21588–600.
44. Aravindan N, Thomas Jr CR, Aravindan S, Mohan AS, Veeraraghavan J, Natarajan
M. Irreversible EGFR inhibitor EKB-569 targets low-LET gamma-radiation-triggered
rel orchestration and potentiates cell death in squamous cell carcinoma. PLoS
One. 2011;6:e29705.
45. Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Low-dose
gamma-radiation-induced oxidative stress response in mouse brain and
gut: regulation by NFkappaB-MnSOD cross-signaling. Mutat Res.
2011;718:44–55.
46. Natarajan M, Aravindan N, Meltz ML, Herman TS. Post-translational modification
of I-kappa B alpha activates NF-kappa B in human monocytes exposed to 56Fe
ions. Radiat Environ Biophys. 2002;41:139–44.
47. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al.
Clinical and biologic features predictive of survival after relapse of
neuroblastoma: a report from the International Neuroblastoma Risk Group
project. J Clin Oncol. 2011;29:3286–92.
48. Kamijo T. Role of stemness-related molecules in neuroblastoma. Pediatr Res.
2012;71:511–5.
49. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA,
et al. Purged versus non-purged peripheral blood stem-cell transplantation
for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet
Oncol. 2013;14:999–1008.
50. Kamijo T, Nakagawara A. Molecular and genetic bases of neuroblastoma. Int
J Clin Oncol. 2012;17:190–5.
51. Khalil MA, Hrabeta J, Cipro S, Stiborova M, Vicha A, Eckschlager T.
Neuroblastoma stem cells - mechanisms of chemoresistance and histone
deacetylase inhibitors. Neoplasma. 2012;59:737–46.
52. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in
cancer. Clin Chem. 2013;59:168–79.
53. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity.
Nature. 2013;501:328–37.
54. Chakrabarti L, Abou-Antoun T, Vukmanovic S, Sandler AD. Reversible adaptive
plasticity: a mechanism for neuroblastoma cell heterogeneity and
chemo-resistance. Front Oncol. 2012;2:82.
55. Chakrabarti L, Wang BD, Lee NH, Sandler AD. A mechanism linking
Id2-TGFbeta crosstalk to reversible adaptive plasticity in neuroblastoma. PLoS
One. 2013;8:e83521.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
